CYTR CYTRX otc stock Story

CYTR -  USA Stock  

USD 1.08  1.74  61.70%

CYTRX CORP Working Capital is relatively stable at the moment as compared to the past year. CYTRX CORP reported last year Working Capital of 15.15 Million. As of 11/14/2020, Receivables Turnover is likely to grow to 0.1, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (7.7 M). While some of us are becoming more passionate about healthcare space, it makes sense to sum up CYTRX CORP in greater detail. What exactly are CYTRX CORP shareholders getting in December? Here I will also sum up some basic indicators that CYTRX CORP investors should consider in December.
Published over six months ago
View all stories for CYTRX CORP | View All Stories
Is CYTRX CORP (OTC:CYTR) finally getting endorsement from retail investors?
The company is undervalued at 1.54 per share with modest projections ahead. The firm shows a Beta (market volatility) of -0.0648, which signifies not very significant fluctuations relative to the market. Let's try to break down what CYTRX's beta means in this case. As returns on the market increase, returns on owning CYTRX CORP are expected to decrease at a much lower rate. During the bear market, CYTRX CORP is likely to outperform the market. Even though it is essential to pay attention to CYTRX CORP historical returns, it is always good to be careful when utilizing equity current trending patterns. Our way in which we are foreseeing any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. CYTRX CORP exposes twenty-one different technical indicators, which can help you to evaluate its performance. CYTRX CORP has an expected return of -0.0838%. Please be advised to confirm CYTRX CORP variance and potential upside to decide if CYTRX CORP stock performance from the past will be repeated at some future point.

Watch out for price decline

Please consider monitoring CYTRX CORP on a daily basis if you are holding a position in it. CYTRX CORP is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the otc stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as CYTRX CORP stock to be traded above the $1 level to remain listed. If CYTRX CORP stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How important is CYTRX CORP's Liquidity

CYTRX CORP financial leverage refers to using borrowed capital as a funding source to finance CYTRX CORP ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. CYTRX CORP financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between CYTRX CORP's total debt and its cash.

How CYTR CYTRX utilizes its cash?

To perform a cash flow analysis of CYTRX CORP, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash CYTRX CORP is receiving and how much cash it distributes out in a given period. The CYTRX CORP cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
CYTRX CORP Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. CYTRX CORP reported last year Net Cash Flow from Operations of (6.14 Million)

Detailed Perspective On CYTRX CORP

CYTRX CORP holds a total of thirty-six million four hundred eighty thousand outstanding shares. CYTRX CORP shows 14.45 percent if its outstanding shares held by insiders and 14.45 percent owned by other corporate entities . Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
 2019 2020 (projected)
Interest Expense1.54 M1.98 M
Gross Profit225 K230.92 K

Ownership Breakdown

Retail Investors
Retail Investors85.49

Are CYTRX CORP technical indicators showing a recoup?

Latest variance is at 35.84. CYTRX CORP exhibits very low volatility with skewness of 0.65 and kurtosis of 7.0. However, we advise investors to further study CYTRX CORP technical indicators to make sure all market info is available and is reliable. CYTRX CORP is a potential penny stock. Although CYTRX CORP may be in fact a good instrument to invest, many penny otc stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in CYTRX CORP. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on this equity instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

Our Final Take On CYTRX CORP

While other entities in the biotechnology industry are either recovering or due for a correction, CYTRX may not be as strong as the others in terms of longer-term growth potentials. To summarize, as of the 14th of November 2020, our overall 30 days buy vs. sell advice on the enterprise is Strong Sell. However, we believe CYTRX CORP is undervalued with very low probability of distress for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of CYTRX CORP. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to